Top

Published in:

Open Access 01-09-2019 | Cytokines | Review

Omnipresence of inflammasome activities in inflammatory bone diseases

Authors: Yael Alippe, Gabriel Mbalaviele

Published in: Seminars in Immunopathology | Issue 5/2019

Abstract

The inflammasomes are intracellular protein complexes that are assembled in response to a variety of perturbations including infections and injuries. Failure of the inflammasomes to rapidly clear the insults or restore tissue homeostasis can result in chronic inflammation. Recurring inflammation is also provoked by mutations that cause the constitutive assembly of the components of these protein platforms. Evidence suggests that chronic inflammation is a shared mechanism in bone loss associated with aging, dysregulated metabolism, autoinflammatory, and autoimmune diseases. Mechanistically, inflammatory mediators promote bone resorption while suppressing bone formation, an imbalance which over time leads to bone loss and increased fracture risk. Thus, while acute inflammation is important for the maintenance of bone integrity, its chronic state damages this tissue. In this review, we discuss the role of the inflammasomes in inflammation-induced osteolysis.

Franchi L, Amer A, Body-Malapel M, Kanneganti TD, Özören N et al (2006) Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1β in salmonella-infected macrophages. Nat Immunol 7(6):576–582PubMed

Guey B, Bodnar M, Manié SN, Tardivel A, Petrilli V (2014) Caspase-1 autoproteolysis is differentially required for NLRP1b and NLRP3 inflammasome function. Proc Natl Acad Sci 111(48):17254–17259PubMedPubMedCentral

Burton L, Paget D, Binder NB, Bohnert K, Nestor BJ et al (2013) Orthopedic wear debris mediated inflammatory osteolysis is mediated in part by NALP3 inflammasome activation. J Orthop Res 31(1):73–80PubMed

Haneklaus M, O’Neill LAJ (2015) NLRP3 at the interface of metabolism and inflammation. Immunol Rev 265(1):53–62PubMed

Schroder K, Zhou R, Tschopp J (2010) The NLRP3 inflammasome: a sensor for metabolic danger? Science (80) 327(5963):296–300

Furman D, Chang J, Lartigue L, Bolen CR, Haddad F et al (2017) Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states. Nat Med 23(2):174–184PubMedPubMedCentral

Lénárt N, Coutts G, Denes A, Rothwell N, Brough D et al (2015) AIM2 and NLRC4 inflammasomes contribute with ASC to acute brain injury independently of NLRP3. Proc Natl Acad Sci 112(13):4050–4055PubMedPubMedCentral

Lugrin J, Martinon F (2018) The AIM2 inflammasome: sensor of pathogens and cellular perturbations. Immunol Rev 281(1):99–114PubMed

Hoffman HM, Broderick L (2016) The role of the inflammasome in patients with autoinflammatory diseases. J Allergy Clin Immunol 138(1):3–14PubMed

10.

Canna SW, Nigrovic PA (2016) Editorial: 21st century storm chasers: defining macrophage activation syndrome. Arthritis Rheum 68(3):557–560

11.

Benseler S, DiMattia MA, Gouni S, Biancotto A, O’Shea JJ et al (2014) An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet 46(10):1140–1146PubMedPubMedCentral

12.

Romberg N, Al Moussawi K, Nelson-Williams C, Stiegler AL, Loring E et al (2014) Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet 46(10):1135–1139PubMedPubMedCentral

13.

Broz P, Dixit VM (2016) Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol 16(7):407–420PubMed

14.

Jin Y, Birlea SA, Fain PR, Spritz RA (2007) Genetic variations in NALP1 are associated with generalized vitiligo in a Romanian population. J Invest Dermatol 127(11):2558–2562PubMed

15.

Jin Y, Mailloux CM, Gowan K, Riccardi SL, LaBerge G et al (2007) NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 356(12):1216–1225PubMed

16.

Lamkanfi M, Dixit VM (2014) Mechanisms and functions of inflammasomes. Cell. 157(5):1013–1022PubMed

17.

Ding J, Wang K, Liu W, She Y, Sun Q et al (2016) Pore-forming activity and structural autoinhibition of the gasdermin family. Nature. 535(7610):111–116PubMed

18.

Evavold CL, Ruan J, Tan Y, Xia S, Wu H, Kagan JC (2018) The pore-forming protein gasdermin D regulates interleukin-1 secretion from living macrophages. Immunity 48(1):35–44.e6PubMed

19.

He WT, Wan H, Hu L, Chen P, Wang X et al (2015) Gasdermin D is an executor of pyroptosis and required for interleukin-1β secretion. Cell Res 25(12):1285–1298PubMedPubMedCentral

20.

Sborgi L, Rühl S, Mulvihill E, Pipercevic J, Heilig R et al (2016) GSDMD membrane pore formation constitutes the mechanism of pyroptotic cell death. EMBO J 35(16):1766–1778PubMedPubMedCentral

21.

Cassel SL, Janczy JR, Bing X, Wilson SP, Olivier AK et al (2014) Inflammasome-independent IL-1 mediates autoinflammatory disease in Pstpip2-deficient mice. Proc Natl Acad Sci 111(3):1072–1077PubMedPubMedCentral

22.

Lukens JR, Gross JM, Calabrese C, Iwakura Y, Lamkanfi M et al (2014) Critical role for inflammasome-independent IL-1 production in osteomyelitis. Proc Natl Acad Sci 111(3):1066–1071PubMedPubMedCentral

23.

Gurung P, Burton A, Kanneganti T-D (2016) NLRP3 inflammasome plays a redundant role with caspase 8 to promote IL-1β–mediated osteomyelitis. Proc Natl Acad Sci 113(16):4452–4457PubMedPubMedCentral

24.

Shi J, Zhao Y, Wang K, Shi X, Wang Y et al (2015) Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 526(7575):660–665PubMed

25.

Kayagaki N, Stowe IB, Lee BL, O’Rourke K, Anderson K et al (2015) Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature. 526(7575):666–671PubMed

26.

Zanoni I, Tan Y, Di Gioia M, Broggi A, Ruan J et al (2016) An endogenous caspase-11 ligand elicits interleukin-1 release from living dendritic cells. Science (80) 352(6290):1232–1236

27.

Sarhan J, Liu BC, Muendlein HI, Li P, Nilson R et al (2018) Caspase-8 induces cleavage of gasdermin D to elicit pyroptosis during Yersinia infection. Proc Natl Acad Sci U S A 115(46):E10888–E10897PubMedPubMedCentral

28.

Orning P, Weng D, Starheim K, Ratner D, Best Z et al (2018) Pathogen blockade of TAK1 triggers caspase-8-dependent cleavage of gasdermin D and cell death. Science. 362(6418):1064–1069PubMedPubMedCentral

29.

Sims NA, Gooi JH (2008) Seminars in cell & developmental biology bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol 19:444–451PubMed

30.

Bellido T, Plotkin LI, Bruzzaniti A (2014) Bone cells. In: Basic and applied bone biology. Elsevier, Milano, pp 27–45

31.

Novack DV, Mbalaviele G (2016) Osteoclasts-key players in skeletal health and disease. Microbiol Spectr 4(3):1–19

32.

Mbalaviele G, Novack DV, Schett G, Teitelbaum SL (2017) Inflammatory osteolysis: a conspiracy against bone. J Clin Invest 127(6):2030–2039PubMedPubMedCentral

33.

Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27(1):519–550PubMed

34.

Yun TJ, Chaudhary PM, Shu GL, Frazer JK, Ewings MK et al (1998) OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol 161(11):6113–6121PubMed

35.

Kanematsu M, Sato T, Takai H, Watanabe K, Ikeda K, Yamada Y (2000) Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. J Bone Miner Res 15(7):1321–1329PubMed

36.

Wang R, Zhang L, Zhang X, Moreno J, Luo X et al (2001) Differential regulation of the expression of CD95 ligand, receptor activator of nuclear factor-kappa B ligand (RANKL), TNF-related apoptosis-inducing ligand (TRAIL), and TNF-alpha during T cell activation. J Immunol 166(3):1983–1990PubMed

37.

Crotti TN, Smith MD, Weedon H, Ahern MJ, Findlay DM et al (2002) Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 61(12):1047–1054PubMedPubMedCentral

38.

Quinn JM, Horwood NJ, Elliott J, Gillespie MT, Martin TJ (2000) Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. J Bone Miner Res 15(8):1459–1466PubMed

39.

Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M et al (2000) Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 191(2):275–286PubMedPubMedCentral

40.

O’Brien W, Fissel BM, Maeda Y, Yan J, Ge X et al (2016) RANK-independent osteoclast formation and bone erosion in inflammatory arthritis. Arthritis Rheum 68(12):2889–2900

41.

Wang C, Hockerman S, Jacobsen EJ, Alippe Y, Selness SR et al (2018) Selective inhibition of the p38α MAPK–MK2 axis inhibits inflammatory cues including inflammasome priming signals. J Exp Med 215(5):1315–1325PubMedPubMedCentral

42.

Lee J, Cho D, Park H (2015) IL-18 and cutaneous inflammatory diseases. Int J Mol Sci 16(12):29357–29369PubMedPubMedCentral

43.

Nakanishi K (2018) Unique action of interleukin-18 on T cells and other immune cells. Front Immunol 9:763PubMedPubMedCentral

44.

Zhang W, Cong X-L, Qin Y-H, He Z-W, He D-Y, Dai S-M (2013) IL-18 upregulates the production of key regulators of osteoclastogenesis from fibroblast-like synoviocytes in rheumatoid arthritis. Inflammation. 36(1):103–109PubMed

45.

Martin TJ, Romas E, Gillespie MT (1998) Interleukins in the control of osteoclast differentiation. Crit Rev Eukaryot Gene Expr 8(2):107–123PubMed

46.

Horwood NJ, Udagawa N, Elliott J, Grail D, Okamura H et al (1998) Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J Clin Invest 101(3):595–603PubMedPubMedCentral

47.

Aglietti RA, Estevez A, Gupta A, Ramirez MG, Liu PS et al (2016) GsdmD p30 elicited by caspase-11 during pyroptosis forms pores in membranes. Proc Natl Acad Sci 113(28):7858–7863PubMedPubMedCentral

48.

Finzel BC, Clancy LL, Holland DR, Muchmore SW, Watenpaugh KD, Einspahr HM (1989) Crystal structure of recombinant human interleukin-1β at 2·0 Å resolution. J Mol Biol 209(4):779–791PubMed

49.

Liu X, Zhang Z, Ruan J, Pan Y, Magupalli VG et al (2016) Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature. 535(7610):153–158PubMedPubMedCentral

50.

Kevin Tracey DJ, Kanneganti T-D, Walle VM, Vitari AC, Amer AO et al (2019) Alarmin HMGB1 in endotoxemia inflammasome-dependent release of the. J Immunol 185:4385–4392

51.

Yang J, Shah R, Robling AG, Templeton E, Yang H et al (2008) HMGB1 is a bone-active cytokine. J Cell Physiol 214(3):730–739PubMed

52.

Von Moltke J, Trinidad NJ, Moayeri M, Kintzer AF, Wang SB et al (2012) Rapid induction of inflammatory lipid mediators by the inflammasome in vivo. Nature. 490(7418):107–111

53.

Charoonpatrapong K, Shah R, Robling AG, Alvarez M, Clapp DW et al (2006) HMGB1 expression and release by bone cells. J Cell Physiol 207(2):480–490PubMed

54.

Chen Y, Sun W, Gao R, Su Y, Umehara H et al (2013) The role of high mobility group box chromosomal protein 1 in rheumatoid arthritis. Rheumatology. 52(10):1739–1747PubMed

55.

Bertheloot D, Latz E (2017) HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins. Cell Mol Immunol 14(1):43–64PubMed

56.

Wang C, Qu C, Alippe Y, Bonar SL, Civitelli R et al (2016) Poly-ADP-ribosylation-mediated degradation of ARTD1 by the NLRP3 inflammasome is a prerequisite for osteoclast maturation. Cell Death Dis 7(3):e2153–e2153PubMedPubMedCentral

57.

Park E, Na HS, Song YR, Shin SY, Kim YM, Chung J (2014) Activation of NLRP3 and AIM2 inflammasomes by Porphyromonas gingivalis infection. Infect Immun 82(1):112–123PubMedPubMedCentral

58.

Bostanci N, Emingil G, Saygan B, Turkoglu O, Atilla G et al (2009) Expression and regulation of the NALP3 inflammasome complex in periodontal diseases. Clin Exp Immunol 157(3):415–422PubMedPubMedCentral

59.

Yamaguchi Y, Kurita-Ochiai T, Kobayashi R, Suzuki T, Ando T (2017) Regulation of the NLRP3 inflammasome in Porphyromonas gingivalis-accelerated periodontal disease. Inflamm Res 66(1):59–65PubMed

60.

McCall SH, Sahraei M, Young AB, Worley CS, Duncan JA et al (2007) Osteoblasts express NLRP3, a nucleotide-binding domain and leucine-rich repeat region containing receptor implicated in bacterially induced cell death. J Bone Miner Res 23(1):30–40PubMedCentral

61.

Josse J, Velard F, Gangloff SC (2015) Staphylococcus aureus vs. osteoblast: relationship and consequences in osteomyelitis. Front Cell Infect Microbiol 5(November):1–17

62.

Scianaro R, Insalaco A, Bracci Laudiero L, De Vito R, Pezzullo M et al (2014) Deregulation of the IL-1β axis in chronic recurrent multifocal osteomyelitis. Pediatr Rheumatol 12(1):30

63.

Levy R, Gérard L, Kuemmerle-Deschner J, Lachmann HJ, Koné-Paut I et al (2014) Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever registry. Ann Rheum Dis 74(11):2043–2049PubMed

64.

Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD (2001) Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 29(3):301–305PubMedPubMedCentral

65.

Hoffman HM, Gregory SG, Mueller JL, Tresierras M, Broide DH et al (2003) Fine structure mapping of CIAS1: identification of an ancestral haplotype and a common FCAS mutation, L353P. Hum Genet 112(2):209–216PubMed

66.

Cordero MD, Alcocer-Gómez E, Ryffel B (2018) Gain of function mutation and inflammasome driven diseases in human and mouse models. J Autoimmun 91:13–22PubMed

67.

Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J (2004) NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity. 20(3):319–325PubMed

68.

Goldbach-Mansky R (2011) Current status of understanding the pathogenesis and management of patients with NOMID/CINCA. Curr Rheumatol Rep 13(2):123–131PubMedPubMedCentral

69.

Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT et al (2002) De novoCIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 46(12):3340–3348PubMedPubMedCentral

70.

Hill SC, Namde M, Dwyer A, Poznanski A, Canna S, Goldbach-Mansky R (2007) Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA). Pediatr Radiol 37(2):145–152PubMed

71.

Yokoyama K, Ikeya M, Umeda K, Oda H, Nodomi S et al (2015) Enhanced chondrogenesis of induced pluripotent stem cells from patients with neonatal-onset multisystem inflammatory disease occurs via the caspase 1-independent cAMP/protein kinase A/CREB pathway. Arthritis Rheum 67(1):302–314

72.

Snouwaert JN, Nguyen MT, Repenning PW, Dye R, Livingston EW et al (2016) An NLRP3 mutation causes arthropathy and osteoporosis in humanized mice. Cell Rep 17(11):3077–3088PubMed

73.

Bonar SL, Brydges SD, Mueller JL, McGeough MD, Pena C et al (2012) Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice. PLoS One 7(4):4–14

74.

Meng G, Zhang F, Fuss I, Kitani A, Strober W (2009) A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity. 30(6):860–874PubMedPubMedCentral

75.

Wang C, Xu C-X, Alippe Y, Qu C, Xiao J et al (2017) Chronic inflammation triggered by the NLRP3 inflammasome in myeloid cells promotes growth plate dysplasia by mesenchymal cells. Sci Rep 7(1):4880PubMedPubMedCentral

76.

Qu C, Bonar SL, Hickman-Brecks CL, Abu-Amer S, McGeough MD et al (2015) NLRP3 mediates osteolysis through inflammation-dependent and -independent mechanisms. FASEB J 29(4):1269–1279PubMed

77.

Xiao J, Wang C, Yao J-C, Alippe Y, Xu C et al (2018) Gasdermin D mediates the pathogenesis of neonatal-onset multisystem inflammatory disease in mice. PLoS Biol 16(11):e3000047PubMedPubMedCentral

78.

McGeough MD, Wree A, Inzaugarat ME, Haimovich A, Johnson CD et al (2017) TNF regulates transcription of NLRP3 inflammasome components and inflammatory molecules in cryopyrinopathies. J Clin Invest 127(12):4488–4497PubMedPubMedCentral

79.

Brydges SD, Broderick L, McGeough MD, Pena CA, Mueller JL, Hoffman HM (2013) Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies. J Clin Invest 123(11):4695–4705PubMedPubMedCentral

80.

Canna SW, De Jesus AA, Gouni S, Brooks SR, Marrero B et al (2014) An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet 46(10):1140–1146PubMedPubMedCentral

81.

Kitamura A, Sasaki Y, Abe T, Kano H, Yasutomo K (2014) An inherited mutation in NLRC4 causes autoinflammation in human and mice. J Exp Med 211(12):2385–2396PubMedPubMedCentral

82.

Park YH, Wood G, Kastner DL, Chae JJ (2016) Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol 17(8):914–921PubMedPubMedCentral

83.

Ben-Chetrit E, Levy M (1998) Familial Mediterranean fever. Lancet. 351(9103):659–664PubMed

84.

Kolly L, Busso N, Palmer G, Talabot-Ayer D, Chobaz V, So A (2010) Expression and function of the NALP3 inflammasome in rheumatoid synovium. Immunology. 129(2):178–185PubMedPubMedCentral

85.

Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC et al (2014) Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Ann Rheum Dis 73(6):1202–1210PubMed

86.

Baum R, Sharma S, Carpenter S, Li Q-Z, Busto P et al (2015) Cutting edge: AIM2 and endosomal TLRs differentially regulate arthritis and autoantibody production in DNase II-deficient mice. J Immunol 194(3):873–877PubMed

87.

Jakobs C, Perner S, Hornung V (2015) AIM2 drives joint inflammation in a self-DNA triggered model of chronic polyarthritis. PLoS One 10(6):e0131702PubMedPubMedCentral

88.

Ippagunta SK, Brand DD, Luo J, Boyd KL, Calabrese C et al (2010) Inflammasome-independent role of apoptosis-associated speck-like protein containing a CARD (ASC) in T cell priming is critical for collagen-induced arthritis. J Biol Chem 285(16):12454–12462PubMedPubMedCentral

89.

Freeman L, Guo H, David CN, Brickey WJ, Jha S, Ting JP-Y (2017) NLR members NLRC4 and NLRP3 mediate sterile inflammasome activation in microglia and astrocytes. J Exp Med 214(5):1351–1370PubMedPubMedCentral

90.

Alippe Y, Wang C, Ricci B, Xiao J, Qu C et al (2017) Bone matrix components activate the NLRP3 inflammasome and promote osteoclast differentiation. Sci Rep 7(1):6630PubMedPubMedCentral

91.

Youm YH, Grant RW, Mccabe LR, Albarado DC, Nguyen KY et al (2013) Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging. Cell Metab 18(4):519–532PubMedPubMedCentral

92.

Maitra R, Clement CC, Scharf B, Crisi GM, Chitta S et al (2009) Endosomal damage and TLR2 mediated inflammasome activation by alkane particles in the generation of aseptic osteolysis. Mol Immunol 47(2–3):175–184PubMedPubMedCentral

93.

Caicedo MS, Samelko L, McAllister K, Jacobs JJ, Hallab NJ (2013) Increasing both CoCrMo-alloy particle size and surface irregularity induces increased macrophage inflammasome activation in vitro potentially through lysosomal destabilization mechanisms. J Orthop Res 31(10):1633–1642PubMedPubMedCentral

94.

Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 440(7081):237–241PubMed

95.

Schlesinger N, Thiele RG (2010) The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis 69(11):1907–1912PubMed

96.

Pazar B, Ea H-K, Narayan S, Kolly L, Bagnoud N et al (2011) Basic calcium phosphate crystals induce monocyte/macrophage IL-1 secretion through the NLRP3 inflammasome in vitro. J Immunol 186(4):2495–2502PubMed

97.

Jin C, Frayssinet P, Pelker R, Cwirka D, Hu B et al (2011) NLRP3 inflammasome plays a critical role in the pathogenesis of hydroxyapatite-associated arthropathy. Proc Natl Acad Sci 108(36):14867–14872PubMedPubMedCentral

98.

de Jesus AA, Goldbach-Mansky R (2013) Monogenic autoinflammatory diseases: concept and clinical manifestations. Clin Immunol 147(3):155–174PubMedCentral

99.

Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N et al (2010) Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 62(1):258–267PubMed

100.

Laino ME, Marrocco R, Rigante D, Stabile A, Leone A et al (2011) Long-term response after 6-year treatment with anakinra and onset of focal bone erosion in neonatal-onset multisystem inflammatory disease (NOMID/CINCA). Rheumatol Int 31(12):1661–1664PubMed

101.

Sibley CH, Plass N, Snow J, Wiggs EA, Brewer CC et al (2012) Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum 64(7):2375–2386PubMedPubMedCentral

102.

Maruotti N, Corrado A, Cantatore FP (2014) Osteoporosis and rheumatic diseases. Reumatismo. 66(2):125PubMed

103.

Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C et al (2011) A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 70(5):747–754PubMed

104.

Tarp S, Amarilyo G, Foeldvari I, Christensen R, Woo JMP et al (2016) Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Rheumatology. 55(4):669–679PubMed

105.

Qu Y, Misaghi S, Newton K, Maltzman A, Izrael-Tomasevic A et al (2016) NLRP3 recruitment by NLRC4 during Salmonella infection. J Exp Med 213(6):877–885PubMedPubMedCentral

106.

Man SM, Hopkins LJ, Nugent E, Cox S, Gluck IM et al (2014) Inflammasome activation causes dual recruitment of NLRC4 and NLRP3 to the same macromolecular complex. Proc Natl Acad Sci 111(20):7403–7408PubMedPubMedCentral

107.

Xu H, Yang J, Gao W, Li L, Li P et al (2014) Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature. 513(7517):237–241PubMed

108.

Haas D, Hoffmann GF (2006) Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome. Orphanet J Rare Dis 1(1):13PubMedPubMedCentral

109.

Lindor NM, Arsenault TM, Solomon H, Seidman CE, McEvoy MT (1997) A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc 72(7):611–615PubMed

110.

Wise CA, Gillum JD, Seidman CE, Lindor NM, Veile R et al (2002) Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 11(8):961–969PubMed

111.

Ibrahim J-N, Jounblat R, Delwail A, Abou-Ghoch J, Salem N et al (2014) Ex vivo PBMC cytokine profile in familial Mediterranean fever patients: involvement of IL-1β, IL-1α and Th17-associated cytokines and decrease of Th1 and Th2 cytokines. Cytokine. 69(2):248–254PubMed

112.

Chae JJ, Cho Y-H, Lee G-S, Cheng J, Liu PP et al (2011) Gain-of-function pyrin mutations induce NLRP3 protein-independent interleukin-1β activation and severe autoinflammation in mice. Immunity. 34(5):755–768PubMedPubMedCentral

113.

Kanneganti A, Malireddi RKS, Saavedra PHV, Vande Walle L, Van Gorp H et al (2018) GSDMD is critical for autoinflammatory pathology in a mouse model of familial Mediterranean fever. J Exp Med 215(6):1519–1529PubMedPubMedCentral

114.

Siebert S, Tsoukas A, Robertson J, McInnes I (2015) Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol Rev 67(2):280–309PubMed

115.

Redlich K, Smolen JS (2012) Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov 11(3):234–250PubMed

116.

Zwerina J, Redlich K, Polzer K, Joosten L, Kronke G et al (2007) TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci 104(28):11742–11747PubMedPubMedCentral

117.

Wei S, Kitaura H, Zhou P, Patrick Ross F, Teitelbaum SL (2005) IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 115(2):282–290PubMedPubMedCentral

118.

Kim S-K, Cho YJ, Choe J-Y (2018) NLRP3 inflammasomes and NLRP3 inflammasome-derived proinflammatory cytokines in peripheral blood mononuclear cells of patients with ankylosing spondylitis. Clin Chim Acta 486:269–274PubMed

119.

Amarasekara DS, Yu J, Rho J (2015) Bone loss triggered by the cytokine network in inflammatory autoimmune diseases. J Immunol Res 2015:1–12

120.

Greenhill CJ, Jones GW, Nowell MA, Newton Z, Harvey AK et al (2014) Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction. Arthritis Res Ther 16(4):419PubMedPubMedCentral

121.

Kolly L, Karababa M, Joosten LAB, Narayan S, Salvi R et al (2009) Inflammatory role of ASC in antigen-induced arthritis is independent of caspase-1, NALP-3, and IPAF. J Immunol 183(6):4003–4012PubMed

122.

Vande Walle L, Van Opdenbosch N, Jacques P, Fossoul A, Verheugen E et al (2014) Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature. 512(7512):69–73PubMed

123.

Holzinger D, Gieldon L, Mysore V, Nippe N, Taxman DJ et al (2012) Staphylococcus aureus Panton-Valentine leukocidin induces an inflammatory response in human phagocytes via the NLRP3 inflammasome. J Leukoc Biol 92(5):1069–1081PubMedPubMedCentral

124.

Claro T, Widaa A, McDonnell C, Foster TJ, O’Brien FJ, Kerrigan SW (2013) Staphylococcus aureus protein A binding to osteoblast tumour necrosis factor receptor 1 results in activation of nuclear factor kappa B and release of interleukin-6 in bone infection. Microbiology 159(Pt_1):147–154PubMed

125.

Kassem A, Henning P, Lundberg P, Souza PPC, Lindholm C, Lerner UH (2015) Porphyromonas gingivalis stimulates bone resorption by enhancing RANKL (receptor activator of NF-κB ligand) through activation of toll-like receptor 2 in osteoblasts. J Biol Chem 290(33):20147–20158PubMedPubMedCentral

126.

Han X, Lin X, Yu X, Lin J, Kawai T et al (2013) Porphyromonas gingivalis infection-associated periodontal bone resorption is dependent on receptor activator of NF-κB ligand. Infect Immun 81(5):1502–1509PubMedPubMedCentral

127.

Akiyama T, Miyamoto Y, Yoshimura K, Yamada A, Takami M et al (2014) Porphyromonas gingivalis-derived lysine gingipain enhances osteoclast differentiation induced by tumor necrosis factor-α and interleukin-1β but suppresses that by interleukin-17A: importance of proteolytic degradation of osteoprotegerin by lysine gingipain. J Biol Chem 289(22):15621–15630PubMedPubMedCentral

128.

Faienza MF, Ventura A, Marzano F, Cavallo L (2013) Postmenopausal osteoporosis: the role of immune system cells. Clin Dev Immunol 2013:1–6

129.

Weitzmann MN, Pacifici R (2006) Review series estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 116(5):1186–1194PubMedPubMedCentral

130.

Charatcharoenwitthaya N, Khosla S, Atkinson EJ, McCready LK, Riggs BL (2007) Effect of blockade of TNF-α and interleukin-1 action on bone resorption in early postmenopausal women. J Bone Miner Res 22(5):724–729PubMed

131.

Roggia C, Gao Y, Cenci S, Weitzmann MN, Toraldo G et al (2001) Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci U S A 98(24):13960–13965PubMedPubMedCentral

132.

Franceschi C, Capri M, Monti D, Giunta S, Olivieri F et al (2007) Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 128(1):92–105PubMed

133.

Liston A, Masters SL (2017) Homeostasis-altering molecular processes as mechanisms of inflammasome activation. Nat Rev Immunol 17(3):208–214PubMed

134.

Kim H, Walsh MC, Takegahara N, Middleton SA, Shin HI et al (2017) The purinergic receptor P2X5 regulates inflammasome activity and hyper-multinucleation of murine osteoclasts. Sci Rep 7(1):1–11

135.

Cobelli N, Scharf B, Crisi GM, Hardin J, Santambrogio L (2011) Mediators of the inflammatory response to joint replacement devices. Nat Rev Rheumatol 7(10):600–608PubMed

136.

Nich C, Takakubo Y, Pajarinen J, Gallo J, Konttinen YT et al (2016) The role of macrophages in the biological reaction to wear debris from artificial joints. J Long-Term Eff Med Implants 26(4):303–309PubMed

137.

MacMullan P, McMahon G, McCarthy G (2011) Detection of basic calcium phosphate crystals in osteoarthritis. Joint Bone Spine 78(4):358–363PubMed

138.

Desai J, Steiger S, Anders H-J (2017) Molecular pathophysiology of gout. Trends Mol Med 23(8):756–768PubMed

139.

Cheung HS (2000) Calcium crystal effects on the cells of the joint: implications for pathogenesis of disease. Curr Opin Rheumatol 12(3):223–227PubMed

140.

So AK, Martinon F (2017) Inflammation in gout: mechanisms and therapeutic targets. Nat Rev Rheumatol 13(11):639–647PubMed

141.

Williams CJ, Qazi U, Bernstein M, Charniak A, Gohr C et al (2018) Mutations in osteoprotegerin account for the CCAL1 locus in calcium pyrophosphate deposition disease. Osteoarthr Cartil 26(6):797–806

142.

Nadra I, Boccaccini AR, Philippidis P, Whelan LC, McCarthy GM et al (2008) Effect of particle size on hydroxyapatite crystal-induced tumor necrosis factor alpha secretion by macrophages. Atherosclerosis. 196(1):98–105PubMed

143.

Narayan S, Pazar B, Ea H-K, Kolly L, Bagnoud N et al (2011) Octacalcium phosphate crystals induce inflammation in vivo through interleukin-1 but independent of the NLRP3 inflammasome in mice. Arthritis Rheum 63(2):422–433PubMed

144.

Ea H-K, Chobaz V, Nguyen C, Nasi S, van Lent P et al (2013) Pathogenic role of basic calcium phosphate crystals in destructive arthropathies. PLoS One 8(2):e57352PubMedPubMedCentral

145.

Clohisy JC, Yamanaka Y, Faccio R, Abu-Amer Y (2006) Inhibition of IKK activation, through sequestering NEMO, blocks PMMA-induced osteoclastogenesis and calvarial inflammatory osteolysis. Journal of Orthopaedic Research 24 (7):1358–1365PubMed

Title: Omnipresence of inflammasome activities in inflammatory bone diseases
Authors: Yael Alippe
Gabriel Mbalaviele
Publication date: 01-09-2019
Publisher: Springer Berlin Heidelberg
Keyword: Cytokines
Published in: Seminars in Immunopathology / Issue 5/2019
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-019-00753-4

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Omnipresence of inflammasome activities in inflammatory bone diseases

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2019

Metabolic reprogramming in osteoclasts

An emerging role for Toll-like receptors at the neuroimmune interface in osteoarthritis

The role of bone cells in immune regulation during the course of infection

γδ T cells in rheumatic diseases: from fundamental mechanisms to autoimmunity

Molecular determinants for the polarization of macrophage and osteoclast

Osteoimmunology: entwined regulation of integrated systems

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page